| Literature DB >> 27246001 |
Jesper Lagergren1, Fredrik Mattsson2, Pernilla Lagergren3.
Abstract
OBJECTIVES: Later weekday of surgery for oesophageal cancer seems to increase 5-year mortality, but the mechanisms are unclear. We hypothesised that early postoperative reoperations and mortality might explain this association, since reoperation after oesophagectomy decreases long-term prognosis, and later weekday of elective surgery increases 30-day mortality.Entities:
Keywords: 30-day mortality; Day of surgery; Oesophageal neoplasm; Postoperative reoperation; Short-term outcomes
Mesh:
Year: 2016 PMID: 27246001 PMCID: PMC4893871 DOI: 10.1136/bmjopen-2016-011097
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Characteristics of 1748 study patients who underwent surgical resection for oesophageal cancer in Sweden in 1987–2010, with follow-up until 2014
| No death/reoperation within 30 days of surgery | Death/reoperation within 30 days of surgery | |
|---|---|---|
| Total | 1490 (100) | 258 (100) |
| Age (years): mean (SD) | 65 (10) | 67 (9) |
| Sex | ||
| Male | 1110 (74) | 195 (76) |
| Female | 380 (26) | 63 (24) |
| Charlson comorbidity index | ||
| 0 | 870 (58) | 145 (56) |
| 1 | 306 (21) | 57 (22) |
| >1 | 314 (21) | 56 (22) |
| Tumour stage | ||
| 0–I | 357 (24) | 54 (21) |
| II | 535 (36) | 104 (40) |
| III–IV | 598 (40) | 100 (39) |
| Tumour histology | ||
| Adenocarcinoma | 675 (45) | 93 (36) |
| Squamous carcinoma | 815 (55) | 165 (64) |
| Neoadjuvant therapy | ||
| No | 1013 (68) | 170 (66) |
| Yes | 477 (32) | 88 (34) |
| Annual surgeon volume | ||
| <17 | 719 (48) | 155 (60) |
| ≥17 | 771 (52) | 103 (40) |
Risk of death or reoperation within 30 days of surgery for oesophageal cancer
| Death/reoperation (n=258) | Death (n=93) | Reoperation (n=191) | Reoperation for anastomotic leak (n=34) | Reoperation with laparotomy (n=54) | Reoperation for wound infection (n=38) | |
|---|---|---|---|---|---|---|
| Weekday of surgery | OR (95% CI)* | OR (95% CI)* | OR (95% CI)* | OR (95% CI)* | OR (95% CI)* | OR (95% CI)* |
| Monday to Tuesday | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Wednesday to Friday | 0.99 (0.75 to 1.31) | 1.28 (0.83 to 1.99) | 0.88 (0.64 to 1.21) | 0.98 (0.47 to 2.02) | 0.75 (0.42 to 1.34) | 1.44 (0.75 to 2.79) |
| Monday | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Tuesday | 0.98 (0.69 to 1.38) | 0.61 (0.33 to 1.11) | 1.00 (0.68 to 1.46) | 0.62 (0.26 to 1.46) | 0.92 (0.47 to 1.80) | 0.96 (0.39 to 2.41) |
| Wednesday | 1.20 (0.81 to 1.78) | 1.16 (0.64 to 2.11) | 1.05 (0.67 to 1.65) | 1.47 (0.62 to 3.49) | 0.74 (0.33 to 1.69) | 1.33 (0.50 to 3.53) |
| Thursday | 0.86 (0.55 to 1.34) | 0.82 (0.42 to 1.61) | 0.81 (0.49 to 1.34) | 0.15 (0.02 to 1.17) | 0.96 (0.42 to 2.20) | 1.54 (0.58 to 4.14) |
| Friday | 0.66 (0.34 to 1.29) | 1.04 (0.44 to 2.44) | 0.54 (0.24 to 1.23) | 0.42 (0.05 to 3.37) | NA | 1.33 (0.35 to 5.13) |
Results presented as OR with 95% CI.
*Adjusted for age, sex, Charlson comorbidity index, tumour stage, tumour histology, neoadjuvant therapy and surgeon volume.
NA, not available.
Risk of death or reoperation within 30 days of surgery for oesophageal cancer, stratified for surgeon volume
| Death/reoperation (n=258) | Death (n=93) | Reoperation (n=191) | Anastomotic (n=34) | Laparotomy (n=54) | Wound within 30 days (n=38) | ||
|---|---|---|---|---|---|---|---|
| Weekday of surgery | Surgeon volume | OR (95% CI)* | OR (95% CI)* | OR (95% CI)* | OR (95% CI)* | OR (95% CI)* | OR (95% CI)* |
| Monday to Tuesday | <17 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Wednesday to Friday | <17 | 1.02 (0.72 to 1.46) | 1.31 (0.78 to 2.20) | 0.88 (0.58 to 1.34) | 0.64 (0.19 to 2.16) | 0.73 (0.36 to 1.48) | 1.55 (0.69 to 3.50) |
| Monday to Tuesday | ≥17 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Wednesday to Friday | ≥17 | 0.94 (0.60 to 1.47) | 1.22 (0.54 to 2.75) | 0.87 (0.54 to 1.42) | 1.26 (0.52 to 3.05) | 0.79 (0.28 to 2.24) | 1.25 (0.40 to 3.87) |
| Monday | <17 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Tuesday | <17 | 0.87 (0.54 to 1.39) | 0.55 (0.25 to 1.17) | 0.90 (0.52 to 1.54) | 0.94 (0.23 to 3.84) | 1.55 (0.65 to 3.67) | 0.53 (0.15 to 1.84) |
| Wednesday | <17 | 1.27 (0.78 to 2.05) | 1.24 (0.63 to 2.45) | 1.11 (0.63 to 1.93) | 0.98 (0.22 to 4.47) | 1.29 (0.50 to 3.33) | 1.26 (0.43 to 3.71) |
| Thursday | <17 | 0.74 (0.41 to 1.32) | 0.72 (0.31 to 1.63) | 0.72 (0.37 to 1.43) | 0.43 (0.05 to 3.90) | 0.82 (0.24 to 2.75) | 1.16 (0.35 to 3.79) |
| Friday | <17 | 0.58 (0.25 to 1.33) | 0.92 (0.34 to 2.49) | 0.32 (0.09 to 1.09) | NA | NA | 0.96 (0.19 to 4.86) |
| Monday | ≥17 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Tuesday | ≥17 | 1.12 (0.67 to 1.87) | 0.73 (0.27 to 2.00) | 1.11 (0.64 to 1.92) | 0.50 (0.17 to 1.47) | 0.36 (0.11 to 1.20) | 2.34 (0.47 to 11.80) |
| Wednesday | ≥17 | 1.00 (0.50 to 2.02) | 0.78 (0.20 to 3.05) | 0.89 (0.41 to 1.94) | 1.89 (0.66 to 5.39) | NA | 1.09 (0.10 to 12.17) |
| Thursday | ≥17 | 1.06 (0.54 to 2.05) | 1.10 (0.35 to 3.49) | 0.92 (0.44 to 1.92) | NA | 1.14 (0.37 to 3.53) | 2.95 (0.48 to 18.16) |
| Friday | ≥17 | 0.85 (0.28 to 2.59) | 1.48 (0.29 to 7.43) | 1.03 (0.33 to 3.16) | 0.85 (0.10 to 7.18) | NA | 2.89 (0.25 to 33.07) |
Results presented as OR with 95% CI.
*Adjusted for age, sex, Charlson comorbidity index, tumour stage, tumour histology, neoadjuvant therapy and surgeon volume.
NA, not available.